Presentation is loading. Please wait.

Presentation is loading. Please wait.

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry  Sean D. Pokorney, MD, MBA,

Published byDominic Parks Modified over 6 years ago

Similar presentations

Presentation on theme: "Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry  Sean D. Pokorney, MD, MBA,"— Presentation transcript:

1 Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry  Sean D. Pokorney, MD, MBA, DaJuanicia N. Simon, MS, Laine Thomas, PhD, Gregg C. Fonarow, MD, Peter R. Kowey, MD, Paul Chang, MD, Daniel E. Singer, MD, MA, Jack Ansell, MD, Rosalia G. Blanco, BA, Bernard Gersh, MB, ChB, DPhil, Kenneth W. Mahaffey, MD, Elaine M. Hylek, MD, MPH, Alan S. Go, MD, Jonathan P. Piccini, MD, MHS, Eric D. Peterson, MD, MPH  American Heart Journal  Volume 170, Issue 1, Pages e1 (July 2015) DOI: /j.ahj Copyright © 2015 The Authors Terms and Conditions

2 Figure 1 Distribution of INR measurements with median TTR and median time above/below therapeutic range displayed. American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2015 The Authors Terms and Conditions

3 Figure 2 Mean number of days until subsequent INR check based on INR values. American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2015 The Authors Terms and Conditions

4 Figure 3 Factors associated with TTR in the lowest quartile (≤53%).
American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2015 The Authors Terms and Conditions

5 Figure 4 A, TTR by CHA2DS2-VASc score. B, TTR by ATRIA score. C, TTR by stage of chronic kidney disease. American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2015 The Authors Terms and Conditions

6 American Heart Journal 2015 170, 141-148.e1DOI: (10.1016/j.ahj.2015.03.017)
Copyright © 2015 The Authors Terms and Conditions

Download ppt "Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry  Sean D. Pokorney, MD, MBA,"

Similar presentations

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.
Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation:

Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation:
Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial.

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial.
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial  Bruce.

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial  Bruce.
CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation 

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation 
Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST)  Kirsten E. Fleischmann,

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST)  Kirsten E. Fleischmann,
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.
Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics  Cheryl Bushnell,

The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics  Cheryl Bushnell,
Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,
Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry.

Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry.
Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation  Hany S. Abed, BPharm, MBBS, PhD,

Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation  Hany S. Abed, BPharm, MBBS, PhD,
Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.
New-onset Atrial Fibrillation Predicts Heart Failure Progression

New-onset Atrial Fibrillation Predicts Heart Failure Progression
American Heart Journal

American Heart Journal
Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria.

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria.
Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice  Manesh R.

Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice  Manesh R.
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the.

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the.
Frontiers of anticoagulation therapy for atrial fibrillation

Frontiers of anticoagulation therapy for atrial fibrillation
National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance  Judith.

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance  Judith.

Similar presentations

Ads by Google